Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRIHEXYPHENIDYL HYDROCHLORIDE vs CHLORZOXAZONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Trihexyphenidyl is an anticholinergic agent that competitively blocks central muscarinic receptors (primarily M1) in the striatum, restoring the balance between acetylcholine and dopamine in the basal ganglia. It also has mild peripheral anticholinergic effects.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Adjunctive therapy for all forms of Parkinson's disease,Treatment of drug-induced extrapyramidal symptoms (e.g., neuroleptic-induced parkinsonism, acute dystonia, akathisia)
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
1 mg orally initially, then increase by 2 mg every 3-5 days up to 6-10 mg daily in 3-4 divided doses; maximum 15 mg/day.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
10-17 hours; clinical context: steady-state concentrations achieved in 2-3 days.
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Primarily metabolized by hepatic microsomal enzymes, with CYP2D6 possibly involved. Elimination half-life is approximately 3–4 hours.
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Renal (primarily as unchanged drug and metabolites; <15% unchanged) and biliary/fecal (minor).
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Minimal; approximately 10-20% bound to plasma proteins (albumin).
Approximately 90–95% bound, primarily to albumin.
Approximately 0.5-1.5 L/kg; indicates extensive tissue distribution.
0.46–0.64 L/kg; indicates distribution into total body water.
Oral: approximately 80-95% (first-pass metabolism minimal).
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
Cr Cl 10-50 m L/min: administer every 8-12 hours; Cr Cl <10 m L/min: consider alternative or reduce dose by 50%.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or use with extreme caution, reduce dose by 75%.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
Children 2-12 years: initial 1 mg/day, increase by 1 mg every 3-5 days; maximum 6 mg/day in divided doses.
Not established; safety and efficacy not studied in pediatric patients.
Start at 1 mg once or twice daily; increase slowly by 1 mg increments every 5-7 days; monitor for anticholinergic side effects.
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
Not applicable.
None
May cause drowsiness, dizziness, or blurred vision; caution with driving or hazardous activities,Anticholinergic effects may be exacerbated in elderly patients, including confusion, constipation, urinary retention, and hyperthermia,Use cautiously in patients with glaucoma, prostatic hypertrophy, cardiac arrhythmias, or myasthenia gravis,Potential for abuse or dependence at high doses,May exacerbate tardive dyskinesia in patients on neuroleptics
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Hypersensitivity to trihexyphenidyl,Narrow-angle glaucoma,Obstructive gastrointestinal disorders (e.g., pyloric stenosis, paralytic ileus),Severe ulcerative colitis or toxic megacolon,Myasthenia gravis
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
No significant food interactions. However, avoid excessive alcohol consumption as it may exacerbate CNS depression and anticholinergic effects. Maintain adequate hydration to prevent constipation and dry mouth.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: No known specific risks; use only if clearly needed.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
No data on M/P ratio; excreted in breast milk in unknown amounts. Caution recommended; avoid if possible.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
No established pharmacokinetic changes requiring dose adjustment; usual therapeutic dose maintained; monitor clinical response.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
Trihexyphenidyl is an anticholinergic agent used primarily for drug-induced parkinsonism and idiopathic Parkinson disease. It is less effective than levodopa but useful as adjunctive therapy. Onset of action is within 1 hour after oral administration; peak effect at 2-3 hours. Monitor for anticholinergic side effects: dry mouth, blurred vision, constipation, urinary retention, and cognitive impairment. Use with caution in elderly patients due to increased risk of confusion and falls. Abrupt withdrawal may precipitate parkinsonian crisis; taper gradually. Avoid in patients with narrow-angle glaucoma, myasthenia gravis, or gastrointestinal obstruction.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,This medication may cause dry mouth, blurred vision, constipation, or difficulty urinating.,Avoid alcohol and other CNS depressants as they may increase drowsiness and dizziness.,Use caution when driving or operating machinery until you know how this drug affects you.,Report any eye pain, vision changes, or difficulty passing urine to your healthcare provider.,Do not chew sustained-release capsules; swallow whole.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double doses.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
"Trihexyphenidyl, an anticholinergic agent, may potentiate the tachycardic effects of nabilone, a synthetic cannabinoid, due to additive inhibition of parasympathetic tone. This interaction can lead to clinically significant sinus tachycardia, palpitations, and potentially exacerbate underlying cardiovascular conditions such as coronary artery disease or arrhythmias."
"The concurrent use of trihexyphenidyl, an anticholinergic agent, with meperidine, an opioid analgesic, increases the risk of severe adverse effects such as central nervous system depression, respiratory depression, and anticholinergic toxicity (e.g., delirium, hyperthermia, and urinary retention). This additive pharmacodynamic interaction occurs due to combined anticholinergic and opioid properties, potentially leading to life-threatening outcomes, especially in elderly or debilitated patients. Clinicians should consider alternative therapies or closely monitor for signs of excessive sedation, respiratory compromise, and anticholinergic crisis."
"Donepezil, a cholinesterase inhibitor used in Alzheimer's disease, increases acetylcholine levels in the central nervous system. Trihexyphenidyl, an anticholinergic agent for Parkinson's disease, blocks muscarinic acetylcholine receptors. Concurrent use results in functional antagonism, where trihexyphenidyl's anticholinergic effects diminish the efficacy of donepezil, potentially worsening cognitive function in Alzheimer's patients."
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRIHEXYPHENIDYL HYDROCHLORIDE vs CHLORZOXAZONE, answered by our medical review team.
TRIHEXYPHENIDYL HYDROCHLORIDE is a Anticholinergic Antiparkinsonian that works by Trihexyphenidyl is an anticholinergic agent that competitively blocks central muscarinic receptors (primarily M1) in the striatum, restoring the balance between acetylcholine and dopamine in the basal ganglia. It also has mild peripheral anticholinergic effects.. CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRIHEXYPHENIDYL HYDROCHLORIDE and CHLORZOXAZONE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRIHEXYPHENIDYL HYDROCHLORIDE is: 1 mg orally initially, then increase by 2 mg every 3-5 days up to 6-10 mg daily in 3-4 divided doses; maximum 15 mg/day.. The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRIHEXYPHENIDYL HYDROCHLORIDE and CHLORZOXAZONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRIHEXYPHENIDYL HYDROCHLORIDE is classified as Category C. First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: No known specific risks; use only if clearly needed.. CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.